A previous study found that Cpd64 (a selective PDK inhibitor) enhances the anticancer activity of EGFR-TKI in EGFR-mutant NSCLC cell lines under hypoxic conditions [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.